Sten at Dr. Essa Lab

Sten at Dr. Essa Lab

The Sten test at Dr. Essa Lab is a highly specialized, state-of-the-art microbiological and molecular diagnostic investigation designed to isolate, identify, and analyze Stenotrophomonas maltophilia. This opportunistic, multi-drug resistant Gram-negative bacillus has emerged as a significant clinical challenge, particularly in hospital settings, intensive care units (ICUs), and among immunocompromised patients. Because Stenotrophomonas maltophilia is naturally resistant to many broad-spectrum antibiotics, including carbapenems, rapid and highly accurate identification through the Sten test is critical for guiding effective antimicrobial therapy and preventing treatment failure.

At Dr. Essa Lab, the Sten diagnostic protocol utilizes advanced automated identification systems, such as the VITEK 2 platform, alongside gold-standard culture techniques and molecular polymerase chain reaction (PCR) assays. This multi-faceted technological approach ensures that the pathogen is identified with exceptional precision. The test evaluates various clinical specimens depending on the site of suspected infection, including sputum, bronchoalveolar lavage (BAL) fluid, blood, urine, wound swabs, and cerebrospinal fluid (CSF). By analyzing these specimens, the clinical microbiologists at Dr. Essa Lab can determine the presence of the bacterium, quantify the bacterial load, and perform comprehensive antibiotic susceptibility testing (AST) to identify the most effective therapeutic agents.

The diagnostic value of the Sten test cannot be overstated. In patients suffering from severe nosocomial pneumonia, bacteremia, or device-related infections, empirical antibiotic treatment often fails due to the unique resistance profile of this pathogen. The Sten test provides clinicians with a definitive microbiological diagnosis and a customized susceptibility profile, detailing the minimum inhibitory concentrations (MICs) of targeted therapeutics such as Trimethoprim-Sulfamethoxazole (TMP-SMX), levofloxacin, minocycline, and ceftazidime. This targeted approach not only improves patient outcomes and survival rates but also plays a vital role in antimicrobial stewardship, reducing the unnecessary use of broad-spectrum drugs and limiting the spread of resistance within healthcare facilities in Karachi and across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to ensure the integrity of the clinical specimen and the accuracy of the Sten test results. Patients and healthcare providers should adhere to the following guidelines:

• Antibiotic Avoidance: Whenever clinically feasible, the specimen for the Sten test should be collected prior to the initiation of any new antimicrobial therapy. If the patient is already receiving antibiotics, this information must be documented on the laboratory requisition form, specifying the drug name, dosage, and duration.
• Sputum Collection Preparation: For respiratory specimens, patients should rinse their mouths thoroughly with sterile water immediately before collection. This minimizes contamination with normal oral flora and saliva. The sample must represent a deep cough specimen, not spit.
• Urine Sample Preparation: If a urine specimen is required, a clean-catch midstream urine sample must be collected. Patients should cleanse the urethral area with sterile water wipes before voiding to prevent contamination from skin flora.
• Blood Culture Preparation: No fasting is required for blood culture collection. However, strict aseptic techniques must be followed by the phlebotomist, including disinfecting the venipuncture site with chlorhexidine or isopropyl alcohol.
• Wound and Fluid Specimens: Wound sites should be cleared of superficial debris and necrotic tissue before obtaining a deep tissue swab or aspirate to ensure the pathogen is isolated from the active site of infection.

During the Procedure

The specimen collection and laboratory analysis process for the Sten test at Dr. Essa Lab is conducted under strict quality control standards to ensure patient safety and diagnostic accuracy:

• Specimen Collection: Depending on the clinical indication, a trained phlebotomist or nurse will collect the appropriate sample. For blood cultures, sterile venipuncture is performed to draw blood directly into specialized aerobic and anaerobic culture bottles. For respiratory or wound infections, sterile swabs, sputum cups, or aspiration syringes are utilized.
• Laboratory Inoculation: Once the specimen arrives at the Dr. Essa Lab microbiology department, it is immediately logged into the laboratory information system and inoculated onto selective and differential media, such as blood agar, MacConkey agar, or specialized selective media designed to inhibit other organisms while promoting the growth of Gram-negative bacilli.
• Incubation and Monitoring: The inoculated plates and culture bottles are incubated at optimal temperatures (typically 35°C to 37°C) in controlled environments. Automated blood culture systems continuously monitor the bottles for signs of bacterial respiration and growth.
• Pathogen Identification: Upon observing bacterial growth, laboratory technologists perform a Gram stain to confirm the presence of Gram-negative rods. Automated systems like VITEK 2 or molecular PCR assays are then deployed to definitively identify the organism as Stenotrophomonas maltophilia.
• Susceptibility Testing: Once identified, the isolate undergoes rigorous antibiotic susceptibility testing (AST) using disk diffusion, gradient strip methods (E-test), or automated MIC determination to map its resistance and susceptibility patterns.
• Duration and Safety: The collection process itself takes only a few minutes and is virtually painless (except for a brief pinch during venipuncture). The laboratory phase requires 24 to 72 hours of incubation to ensure robust bacterial growth and accurate susceptibility profiling.

When is a Sten Performed?

Suspected Nosocomial Infections

The Sten test is frequently requested for hospitalized patients, particularly those in intensive care units (ICUs) who have been subjected to prolonged hospital stays. Stenotrophomonas maltophilia is a notorious opportunistic pathogen in clinical environments, often colonizing medical equipment, respiratory therapy devices, and indwelling catheters. When a hospitalized patient develops a new fever, increased inflammatory markers, or worsening respiratory status, physicians order the Sten test to rule out or confirm a hospital-acquired infection caused by this resilient bacterium, allowing for immediate isolation protocols and targeted therapy.

Immunocompromised Patient Monitoring

Patients with compromised immune systems, such as those undergoing active chemotherapy for cancer, bone marrow or solid organ transplant recipients, and individuals with advanced HIV/AIDS, are at an exceptionally high risk for opportunistic infections. In these patient populations, Stenotrophomonas maltophilia can cause rapidly progressive and life-threatening infections, including bacteremia and severe pneumonia. Physicians utilize the Sten test at the earliest signs of infection—such as chills, neutropenic fever, or localized pain—to identify the pathogen quickly and initiate life-saving, targeted antimicrobial regimens.

Chronic Respiratory Conditions

Individuals suffering from chronic, debilitating pulmonary diseases, most notably cystic fibrosis (CF), bronchiectasis, or severe chronic obstructive pulmonary disease (COPD), are highly susceptible to bacterial colonization and subsequent pulmonary exacerbations. Stenotrophomonas maltophilia frequently colonizes the thick mucus in the airways of these patients. When a patient with cystic fibrosis presents with increased cough, sputum production, dyspnea, or a decline in lung function (FEV1), the Sten test is performed on sputum or bronchoalveolar lavage fluid to differentiate between simple colonization and an active, tissue-invasive infection requiring aggressive treatment.

Unresponsive Bacterial Infections

A primary clinical indication for ordering the Sten test is when a patient with an ongoing bacterial infection fails to respond to standard, broad-spectrum antibiotic therapies, particularly carbapenems (such as imipenem or meropenem) or third-generation cephalosporins. Because Stenotrophomonas maltophilia possesses intrinsic resistance mechanisms against these widely used drugs, empirical treatment will fail, leading to clinical deterioration. Performing the Sten test allows clinicians to identify this specific pathogen and pivot the treatment plan toward effective agents like Trimethoprim-Sulfamethoxazole.

Post-Surgical and Device-Related Complications

Patients who have recently undergone major surgical procedures or those with indwelling medical devices—such as central venous catheters, urinary catheters, prosthetic heart valves, or mechanical ventilators—are vulnerable to biofilm-associated infections. Stenotrophomonas maltophilia is highly proficient at forming robust biofilms on synthetic surfaces, shielding itself from both the host immune response and standard antibiotics. The Sten test is indicated when there is suspected catheter-related bloodstream infection (CRBSI), surgical site infection, or ventilator-associated pneumonia (VAP) to confirm biofilm involvement and guide device removal and therapeutic decisions.

What Does a Sten Detect?

The Sten test at Dr. Essa Lab is designed to detect and analyze a comprehensive array of microbiological, biochemical, and molecular parameters associated with Stenotrophomonas maltophilia. The test specifically evaluates and detects:

• The presence or absence of viable Stenotrophomonas maltophilia in the clinical specimen.
• Bacterial colony-forming units (CFU/mL) to determine the severity and load of the infection.
• Gram-negative rod-shaped bacillus morphology under microscopic examination.
• Oxidase-negative biochemical reaction, a key distinguishing feature of this genus.
• Catalase-positive reaction, indicating the organism’s oxidative metabolic capabilities.
• Motility characteristics, confirming the presence of polar flagella.
• Maltose oxidation, demonstrating the bacterium’s classic metabolic pathway.
• Susceptibility or resistance to Trimethoprim-Sulfamethoxazole (TMP-SMX), the primary therapeutic agent.
• Susceptibility or resistance to fluoroquinolones, specifically Levofloxacin.
• Susceptibility or resistance to tetracycline derivatives, including Minocycline.
• Susceptibility or resistance to Ceftazidime, a third-generation cephalosporin.
• Intrinsic resistance to Carbapenems (imipenem and meropenem), confirming the pathogen’s identity.
• Production of L1 metallo-beta-lactamase enzymes, which hydrolyze carbapenems.
• Production of L2 serine active-site beta-lactamase enzymes, contributing to cephalosporin resistance.
• Biofilm-producing capacity of the isolated bacterial strain.
• Polymicrobial growth, identifying co-pathogens such as Pseudomonas aeruginosa or Klebsiella pneumoniae.
• Contamination of the specimen with normal respiratory or skin flora.
• Minimum Inhibitory Concentration (MIC) values for all tested antimicrobial agents.
• Molecular detection of specific resistance genes via targeted PCR assays.
• Culture purity, verifying whether the infection is monomicrobial.
• Presence of inflammatory cells, such as polymorphonuclear leukocytes (PMNs), indicating active host response.
• Absence of pathogenic growth, confirming a sterile culture in negative cases.
• Growth delay or slow-growing variants that may require extended incubation.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are critical for managing severe, drug-resistant infections. Preliminary results for the Sten test, including Gram stain findings and initial culture growth observations, are typically available within 24 hours of specimen receipt. Complete identification of Stenotrophomonas maltophilia and its comprehensive antibiotic susceptibility profile (AST) are finalized within 48 to 72 hours. This timeframe is necessary to ensure the bacteria undergo adequate incubation for highly accurate resistance mapping.

Patients and healthcare providers can access reports seamlessly through Dr. Essa Lab’s advanced digital infrastructure. Once the consultant microbiologist signs off on the final report, an automated SMS notification containing a secure download link is sent to the patient’s registered mobile number. Reports can also be viewed and downloaded directly from the official Dr. Essa Lab website or mobile application. For convenience, printed copies of the reports can be collected from any of our numerous diagnostic centers located across Karachi and other major cities in Pakistan.

Sten Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Specimen Culture	No growth of Stenotrophomonas maltophilia	Isolation and growth of Stenotrophomonas maltophilia colonies
Gram Stain Morphology	No bacteria observed or normal flora only	Gram-negative rod-shaped bacilli detected
Automated Identification (VITEK 2)	Negative for pathogenic Gram-negative bacilli	Definitive identification of Stenotrophomonas maltophilia (99% probability)
TMP-SMX Susceptibility	Not applicable (no growth)	Susceptible (MIC ≤ 2/38 µg/mL) or Resistant (MIC ≥ 4/76 µg/mL)
Carbapenem Susceptibility	Not applicable	Intrinsic resistance to Imipenem and Meropenem (high MIC values)
Polymorphonuclear Leukocytes (PMNs)	None to few leukocytes observed	Abundant PMNs (moderate to severe inflammatory response)
Molecular PCR Detection	Negative for S. maltophilia specific DNA	Positive detection of Stenotrophomonas maltophilia genomic DNA
Biofilm Formation Assay	No biofilm production detected	Moderate to strong biofilm-producing strain isolated

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Sten?

• Legacy of Trust: Established in 1987 by Prof. Dr. Farhan Essa Abdullah, Dr. Essa Lab is one of Pakistan’s most trusted diagnostic networks.
• ISO Certification: Operating under strict international quality standards with ISO 9001:2015 certification to ensure diagnostic precision.
• Expert Pathologists: Reports are analyzed and signed off by highly qualified consultant microbiologists and pathologists.
• State-of-the-Art Technology: Equipped with advanced automated systems like VITEK 2 and high-throughput PCR machines for rapid pathogen identification.
• Extensive Branch Network: Conveniently located diagnostic centers across Karachi and other major cities for easy sample drop-off.
• Home Sample Collection: Highly trained phlebotomists available to collect specimens from the comfort of your home, maintaining strict cold chain protocols.
• Seamless Digital Access: Easy online report retrieval via our website, dedicated mobile app, and instant SMS notifications.
• Antimicrobial Stewardship Support: Providing highly detailed MIC values to help clinicians design precise, targeted antibiotic therapies and combat drug resistance.